Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

UTHR | United Therapeutics Corporation

Index- P/E12.60 EPS (ttm)17.68 Insider Own0.20% Shs Outstand46.90M Perf Week1.14%
Market Cap10.42B Forward P/E10.64 EPS next Y20.94 Insider Trans-76.31% Shs Float46.08M Perf Month-3.76%
Income871.50M PEG1.30 EPS next Q5.05 Inst Own99.97% Short Float / Ratio2.37% / 3.38 Perf Quarter0.18%
Sales2.11B P/S4.94 EPS this Y49.10% Inst Trans1.02% Short Interest1.09M Perf Half Y3.12%
Book/sh115.37 P/B1.93 EPS next Y8.17% ROA14.00% Target Price284.60 Perf Year8.36%
Cash/sh57.28 P/C3.89 EPS next 5Y9.70% ROE17.50% 52W Range201.65 - 283.09 Perf YTD-19.90%
Dividend- P/FCF15.47 EPS past 5Y6.60% ROI13.50% 52W High-21.31% Beta0.62
Dividend %- Quick Ratio8.40 Sales past 5Y2.30% Gross Margin89.90% 52W Low10.46% ATR4.38
Employees985 Current Ratio8.70 Sales Q/Q27.80% Oper. Margin51.50% RSI (14)44.77 Volatility2.01% 1.81%
OptionableYes Debt/Eq0.15 EPS Q/Q117.10% Profit Margin41.30% Rel Volume0.51 Prev Close223.68
ShortableYes LT Debt/Eq0.15 EarningsAug 02 BMO Payout0.00% Avg Volume323.84K Price222.75
Recom2.00 SMA20-0.76% SMA50-4.04% SMA200-6.05% Volume163,673 Change-0.42%
Date Action Analyst Rating Change Price Target Change
Dec-06-22Initiated UBS Buy $320
Dec-05-22Initiated Goldman Sell $230
Oct-11-22Initiated Morgan Stanley Overweight $288
Sep-20-22Reiterated BofA Securities Underperform
Sep-19-22Resumed Wedbush Outperform $263
Feb-11-22Initiated BTIG Research Neutral
Jul-14-21Upgrade Argus Hold → Buy $205
Apr-26-21Resumed Credit Suisse Outperform $196
Feb-01-21Upgrade H.C. Wainwright Neutral → Buy $125 → $195
Sep-14-20Resumed JP Morgan Overweight $142
Sep-22-23 11:01PM
02:15PM
Sep-12-23 06:00AM
Sep-09-23 01:03AM
Sep-01-23 06:00AM
10:00AM Loading…
Aug-20-23 10:00AM
Aug-08-23 11:33AM
Aug-04-23 12:16PM
07:28AM
Aug-02-23 12:29PM
09:30AM
07:15AM
06:06AM
06:00AM
Jul-26-23 01:23PM
06:00AM Loading…
06:00AM
Jul-25-23 02:37PM
08:25AM
Jul-24-23 11:45AM
Jul-20-23 07:20AM
Jul-13-23 06:56AM
06:41AM
Jul-10-23 09:47AM
Jun-14-23 06:00AM
Jun-08-23 11:30AM
May-25-23 04:03AM
May-19-23 08:35AM
May-05-23 03:13PM
May-04-23 09:04AM
May-03-23 11:11PM
04:52PM Loading…
04:52PM
09:30AM
07:15AM
06:06AM
06:00AM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
06:00AM
Apr-24-23 06:59AM
Apr-19-23 07:22PM
Apr-18-23 06:00AM
Mar-27-23 11:02AM
Mar-24-23 11:30AM
Mar-17-23 03:22AM
Mar-07-23 07:12PM
Mar-06-23 04:30PM
Feb-28-23 05:57PM
06:00AM
Feb-27-23 07:56AM
Feb-23-23 12:06PM
10:50AM
06:12AM
Feb-22-23 07:15AM
06:00AM
05:30AM
Feb-21-23 11:09AM
Feb-16-23 10:01AM
Feb-15-23 06:00AM
Feb-13-23 09:00AM
Feb-05-23 08:49PM
Jan-30-23 07:55AM
Jan-27-23 11:40AM
Jan-25-23 10:37AM
Jan-21-23 06:34PM
Jan-19-23 09:35AM
Jan-11-23 07:10AM
06:55AM
Jan-09-23 10:01PM
11:40AM
Jan-06-23 06:50PM
07:29AM
Jan-05-23 04:19PM
Jan-04-23 10:41AM
10:00AM
Jan-02-23 06:00AM
Dec-22-22 10:53AM
Dec-21-22 09:51AM
Dec-16-22 05:28AM
Dec-15-22 11:40AM
10:09AM
07:59AM
Dec-09-22 05:42PM
Dec-08-22 06:00AM
05:12AM
Dec-07-22 06:44AM
Dec-06-22 09:22AM
Dec-02-22 11:31AM
Dec-01-22 09:40AM
Nov-28-22 11:40AM
Nov-25-22 03:20PM
Nov-24-22 03:04PM
Nov-11-22 11:40AM
Nov-10-22 12:20PM
Nov-07-22 09:40AM
08:35AM
Nov-03-22 11:32AM
Nov-02-22 02:47PM
07:15AM
06:00AM
Nov-01-22 06:00AM
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAHON PAUL AEVP & GENERAL COUNSELSep 21Option Exercise117.766,000706,56042,599Sep 22 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELSep 21Sale222.196,0001,333,15036,599Sep 22 04:30 PM
Mesa NildaDirectorSep 13Sale222.3638385,1646,303Sep 15 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELSep 07Option Exercise117.766,000706,56042,599Sep 08 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELSep 07Sale222.986,0001,337,90536,599Sep 08 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELAug 17Option Exercise117.766,000706,56042,599Aug 18 04:30 PM
PATUSKY CHRISTOPHERDirectorAug 17Option Exercise88.032,000176,0603,684Aug 18 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELAug 17Sale229.546,0001,377,26536,599Aug 18 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELAug 03Option Exercise117.766,000706,56042,599Aug 04 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELAug 03Sale236.256,0001,417,47036,599Aug 04 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELJul 20Option Exercise120.262,500300,65039,099Jul 24 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELJul 20Sale243.872,500609,67536,599Jul 24 04:30 PM
SULLIVAN LOUIS WDirectorJul 07Option Exercise0.00880013,060Jul 07 04:30 PM
Thompson Tommy GDirectorJul 07Option Exercise0.0088008,480Jul 07 04:30 PM
Olian Judy D.DirectorJul 07Option Exercise0.001,75008,255Jul 07 04:30 PM
Mesa NildaDirectorJul 07Option Exercise0.0088006,686Jul 07 04:30 PM
KURZWEIL RAYDirectorJul 07Option Exercise0.00880011,180Jul 07 04:30 PM
Klein Katherine JDirectorJul 07Option Exercise0.0088003,640Jul 07 04:30 PM
DWEK RAYMONDDirectorJul 07Option Exercise0.001,75001,750Jul 07 04:30 PM
Giltner RichardDirectorJul 07Option Exercise0.001,750015,620Jul 07 04:30 PM
CAUSEY CHRISTOPHERDirectorJul 07Option Exercise0.001,75004,585Jul 07 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELJul 06Option Exercise120.266,000721,56042,599Jul 07 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELJul 06Sale215.196,0001,291,16536,599Jul 07 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELJun 15Option Exercise120.266,000721,56042,599Jun 15 05:23 PM
MAHON PAUL AEVP & GENERAL COUNSELJun 15Sale227.776,0001,366,63436,599Jun 15 05:23 PM
Thompson Tommy GDirectorJun 13Option Exercise88.031,00088,0308,600Jun 14 04:30 PM
Thompson Tommy GDirectorJun 02Option Exercise88.031,00088,0308,600Jun 05 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELJun 01Option Exercise120.266,000721,56042,599Jun 01 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELJun 01Sale209.116,0001,254,67736,599Jun 01 04:30 PM
Giltner RichardDirectorMay 22Option Exercise63.905,000319,50018,870May 23 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELMay 18Option Exercise120.266,000721,56042,599May 18 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELMay 18Sale214.586,0001,287,47336,599May 18 04:30 PM
PATUSKY CHRISTOPHERDirectorMay 10Option Exercise88.032,000176,0603,684May 11 04:30 PM
Mesa NildaDirectorMay 05Sale214.8137480,3375,806May 08 05:16 PM
MAHON PAUL AEVP & GENERAL COUNSELMay 04Option Exercise120.266,000721,56042,599May 04 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELMay 04Sale215.826,0001,294,90336,599May 04 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMay 02Option Exercise113.088,000904,6408,130May 03 04:31 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMay 02Sale228.598,0001,828,685130May 03 04:31 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMay 01Option Exercise113.088,000904,6408,130May 02 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMay 01Sale231.408,0001,851,202130May 02 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 28Option Exercise113.088,000904,6408,130May 02 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 28Sale229.328,0001,834,584130May 02 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 27Option Exercise113.088,000904,6408,130Apr 28 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 27Sale226.508,0001,812,022130Apr 28 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 26Option Exercise113.088,000904,6408,130Apr 28 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 26Sale226.018,0001,808,056130Apr 28 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 25Option Exercise113.088,000904,6408,130Apr 26 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 25Sale226.048,0001,808,313130Apr 26 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 24Option Exercise113.088,000904,6408,130Apr 26 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 24Sale228.648,0001,829,145130Apr 26 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 21Option Exercise113.088,000904,6408,130Apr 24 04:30 PM
DWEK RAYMONDDirectorApr 21Option Exercise63.902,000127,8002,000Apr 24 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 21Sale228.828,0001,830,557130Apr 24 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 20Option Exercise113.088,000904,6408,130Apr 24 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 20Option Exercise120.266,000721,56042,599Apr 20 05:00 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 20Sale224.908,0001,799,227130Apr 24 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 20Sale223.966,0001,343,75536,599Apr 20 05:00 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 19Option Exercise113.088,000904,6408,130Apr 20 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 19Sale226.128,0001,808,988130Apr 20 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 18Option Exercise113.088,000904,6408,130Apr 20 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 18Sale226.788,0001,814,271130Apr 20 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 17Option Exercise113.088,000904,6408,130Apr 18 04:33 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 17Sale230.478,0001,843,763130Apr 18 04:33 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 14Option Exercise113.088,000904,6408,130Apr 18 04:33 PM
DWEK RAYMONDDirectorApr 14Option Exercise63.902,000127,8002,000Apr 18 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 14Sale228.488,0001,827,876130Apr 18 04:33 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 13Option Exercise113.088,000904,6408,130Apr 14 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 13Sale230.698,0001,845,541130Apr 14 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 12Option Exercise113.088,000904,6408,130Apr 14 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 12Sale227.158,0001,817,199130Apr 14 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 11Option Exercise113.088,000904,6408,130Apr 12 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 11Sale225.578,0001,804,555130Apr 12 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 10Option Exercise113.088,000904,6408,130Apr 12 04:30 PM
DWEK RAYMONDDirectorApr 10Option Exercise63.903,000191,7003,000Apr 12 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 10Sale224.218,0001,793,684130Apr 12 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 06Option Exercise113.088,000904,6408,130Apr 07 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 06Option Exercise120.266,000721,56042,599Apr 07 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 06Sale229.128,0001,832,925130Apr 07 04:30 PM
MAHON PAUL AEVP & GENERAL COUNSELApr 06Sale232.796,0001,396,75536,599Apr 07 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 05Option Exercise113.088,000904,6408,130Apr 07 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 05Sale231.358,0001,850,776130Apr 07 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 04Option Exercise113.088,000904,6408,130Apr 05 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 04Sale226.268,0001,810,064130Apr 05 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 03Option Exercise113.088,000904,6408,130Apr 05 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOApr 03Sale225.048,0001,800,327130Apr 05 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 31Option Exercise113.088,000904,6408,130Apr 03 04:51 PM
Thompson Tommy GDirectorMar 31Option Exercise63.902,500159,75010,100Apr 03 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 31Sale221.538,0001,772,202130Apr 03 04:51 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 30Option Exercise113.088,000904,6408,130Mar 31 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 30Sale217.148,0001,737,091130Mar 31 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 29Option Exercise113.088,000904,6408,130Mar 31 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 29Sale217.538,0001,740,270130Mar 31 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 28Option Exercise113.088,000904,6408,130Mar 30 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 28Sale219.988,0001,759,803130Mar 30 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 27Option Exercise113.088,000904,6408,130Mar 28 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 27Sale217.048,0001,736,314130Mar 28 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 24Option Exercise113.088,000904,6408,130Mar 28 04:30 PM
Thompson Tommy GDirectorMar 24Option Exercise63.902,500159,75010,100Apr 03 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 24Sale217.958,0001,743,592130Mar 28 04:30 PM
ROTHBLATT MARTINE ACHAIRPERSON & CEOMar 23Option Exercise113.088,000904,6408,130Mar 24 04:30 PM